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GCN2 is required to increase fibroblast growth factor 21 and maintain
hepatic triglyceride homeostasis during asparaginase treatment. Am J
Physiol Endocrinol Metab 308: E283–E293, 2015. First published
December 9, 2014; doi:10.1152/ajpendo.00361.2014.—The antileu-
kemic agent asparaginase triggers the amino acid response (AAR) in
the liver by activating the eukaryotic initiation factor 2 (eIF2) kinase
general control nonderepressible 2 (GCN2). To explore the mecha-
nism by which AAR induction is necessary to mitigate hepatic lipid
accumulation and prevent liver dysfunction during continued aspara-
ginase treatment, wild-type and Gcn2 null mice were injected once
daily with asparaginase or phosphate buffered saline for up to 14 days.
Asparaginase induced mRNA expression of multiple AAR genes and
greatly increased circulating concentrations of the metabolic hormone
fibroblast growth factor 21 (FGF21) independent of food intake. Loss
of Gcn2 precluded mRNA expression and circulating levels of FGF21
and blocked mRNA expression of multiple genes regulating lipid
synthesis and metabolism including Fas, Ppara, Pparg, Acadm, and
Scd1 in both liver and white adipose tissue. Furthermore, rates of
triglyceride export and protein expression of apolipoproteinB-100
were significantly reduced in the livers of Gcn2 null mice treated with
asparaginase, providing a mechanistic basis for the increase in hepatic
lipid content. Loss of AAR-regulated antioxidant defenses in Gcn2
null livers was signified by reduced Gpx1 gene expression alongside
increased lipid peroxidation. Substantial reductions in antithrombin III
hepatic expression and activity in the blood of asparaginase-treated
Gcn2 null mice indicated liver dysfunction. These results suggest that
the ability of the liver to adapt to prolonged asparaginase treatment is
influenced by GCN2-directed regulation of FGF21 and oxidative
defenses, which, when lost, corresponds with maladaptive effects on
lipid metabolism and hemostasis.
general control nonderepressible 2; amino acid response; antithrombin
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NUTRIENT CONTROL OF MAMMALIAN PROTEIN SYNTHESIS involves a
complex interplay of regulators including the eukaryotic initi-
ation factor 2 (eIF2) kinase general control nonderepressible 2
(GCN2). GCN2 is a direct sensor of amino acid supply,
activated via binding deacylated tRNAs proximal to the ribo-
some (41). Activation of GCN2 during dietary amino acid
deprivation or imbalance increases eIF2 phosphorylation (2, 25).
Phosphorylation of eIF2 functions to slow or stall the initiation
step of mRNA translation, reducing general protein synthesis rates
(6). The resultant delay in reinitiation rate also alters gene-specific
mRNA translation, so as to favor the synthesis of a subset of basic
leucine zipper (bZIP) transcription factors that contain upstream
open reading frames in the 5=-untranslated region. Synthesis of
these bZIP proteins, such as activating transcription factor 4
(ATF4) (48), collectively alters mRNA expression of other bZIP
factors as well as genes that alter amino acid synthesis and
metabolism, nutrient uptake, redox status, and cell cycle control
(26, 27). This realignment of gene expression is called the amino
acid response (AAR), and its homeostatic function helps the
organism accommodate and if possible adapt to amino acid-
deprived conditions (33).
Previous reports from our laboratory and others demonstrate
that mice deleted for Gcn2 fail to phosphorylate eIF2 during
both dietary and pharmaceutical amino acid deprivation, re-
sulting in hepatic steatosis and liver injury (2, 12, 24, 43, 50).
Depletion of circulating asparagine and glutamine is accom-
plished by asparaginase (37, 39), an effective tumor killing
agent in patients diagnosed with acute lymphoblastic leukemia.
Among the metabolic complications that correlate with aspar-
aginase, hepatic steatosis and dysfunction feature prominently
(13, 21, 42). A means to predict or prevent metabolic compli-
cations by asparaginase remains elusive.
In intact mice, asparaginase promotes hepatic lipid accumu-
lation. The degree of steatosis is maximal during the first week
of treatment, resolving steadily thereafter (20). To determine if
loss of the AAR precludes resolution of hepatic stress to
asparaginase, treatment was extended to 14 days in both
wild-type and Gcn2 null mice. To clarify the relationship
between hepatotoxicity and lipid metabolism during asparagi-
nase treatment, we endeavored to understand the role of the
AAR in preventing and/or resolving liver steatosis during
asparaginase. To this end, we examined a series of genes and
proteins involved in lipid metabolism, including metabolic
hormone fibroblast growth factor 21 (FGF21) by the AAR.
FGF21 is a circulating hormone that induces hepatic fat oxi-
dation, ketogenesis, and gluconeogenesis in the liver in re-
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sponse to fasting (51). Recent studies demonstrate that amino
acid-deficient diets increase expression of FGF21 via ATF4
(18, 34). Herein, we describe for the first time that asparaginase
promotes expression of FGF21 in a GCN2-dependent fashion.
Loss of FGF21 expression during asparaginase treatment in the
GCN2 null mouse corresponded to deranged lipid homeostasis
in liver and white adipose tissue, promoting lipotoxicity and
hepatic dysfunction.
MATERIALS AND METHODS
Animals and diets. Male and female Gcn2/ mice (backcrossed to
C57BL/6J for 10 generations) and C57BL/6J wild-type control mice
(Jackson Laboratories, Bar Harbor, ME) aged 8–9 wk were housed in
plastic cages with wired bottoms. Mice were pair fed the same amount
of commercial rodent chow (5001 Laboratory Rodent Diet; LabDiet)
as that consumed by Gcn2/ mice given asparaginase. Mice were
exposed to a 12:12-h light-dark cycle and had free access to water. All
animal protocols were approved by the Institutional Animal Care and
Use Committees at Rutgers, The State University of New Jersey.
L-Asparaginase activity. L-Asparaginase is an antileukemic agent
that depletes circulating levels of asparagine. The activity of aspara-
ginase derived from Escherichia coli (Elspar; Merck) was determined
by the Nesslerization technique, as previously described (11, 43).
Briefly, the production of ammonia by asparaginase over time was
measured and compared with known ammonia standards. Resulting
values represented the activity of the enzyme in international units
(IU), where one IU equaled the amount of enzyme that catalyzed the
formation of 1 mol of ammonia/min.
Experimental procedure. Mice received once-daily intraperitoneal
injections of either L-asparaginase (3 IU per g body wt) or an
equivalent volume of PBS for up to 14 days. The experimental design
consisted of four treatment groups: WP, C57BL/6J wild-type mice
injected with PBS; WA, wild-type mice injected with asparaginase;
GP, Gcn2/ mice injected with PBS; and GA, Gcn2/ mice
injected with asparaginase. At the start of the experiment, average
body weight of each treatment group was 20 g (individual mice in
each group ranged 17–25 g). Mice that lost greater than 20% body
wt from the start of treatment and displayed severe morbidity were
euthanized. Seven hours after the final injection, mice were eutha-
nized by decapitation and trunk blood was collected to obtain serum.
Whole organs or tissues were rapidly dissected, rinsed in ice-cold
PBS, blotted, and weighed.
Histology. Tissues fixed in 4% paraformaldehyde were frozen and
then sectioned (10 m) using a cryostat. Frozen sections were stained
with Oil Red O to visualize lipid as described previously (50).
Paraffin-embedded liver specimens were sectioned (6 m) and stained
with hematoxylin and eosin to visualize general histology and identify
histopathological features under light microscopy.
Hepatic triglyceride secretion. Very low density lipoprotein-tri-
glyceride (VLDL-TG) secretion rates were calculated from the slope
of the regression line describing the rate of rise in blood triglycerides
during blockage of intravascular lipolysis after tyloxapol injection
(Triton WR1339; Sigma-Aldrich, St. Louis, MO). Tyloxapol is an
inhibitor of blood triglyceride clearance, as previously described (28).
Briefly, mice were food deprived overnight, and after morning treat-
ment with asparaginase or PBS, mice were intraperitoneally injected
with tyloxapol at a dose of 500 mg/kg. A drop of blood was drawn at
20-min intervals, and blood triglyceride concentrations were mea-
sured immediately with a handheld meter and test strips (Polymer
Technology Systems; CardioChek, Indianapolis, IN). Tyloxapol
blocks circulating triglyceride degradation, such that blood triglycer-
ide levels rise linearly, and the linear regression slope (change in
concentration/time) indicates secretion rate (28). Rates in units of
mg·dl1·min1 were converted to absolute rates (mg/min) based on
the assumption of 110 ml blood/kg body wt. We consistently found
high linearity (R2 0.99) with sufficient data points for precise
calculation of slope. Following assessment of the triglyceride secre-
tion rate, mice were euthanized by carbon dioxide inhalation.
Hepatic triglyceride concentration. Triglycerides were measured
from frozen liver tissue (40 mg) using the Biovision Colorimetric
Triglyceride Quantification Kit (Mountain View, CA), following the
manufacturer’s instructions.
Protein carbonylation. Carbonylated proteins are a biomarker of
oxidative stress and were measured in livers using the Biovision
Protein Carbonyl Content Assay Kit, following the manufacturer’s
instructions. Briefly, protein carbonyls were tagged by 2,4-dinitrophe-
nyl hydrazones, and the reactant product was measured by spectro-
phometry analysis at 375 nm using spectramax plate reader (Mo-
lecular Devices, Sunnyvale, CA).
Fig. 1. General control nonderepressible 2
(Gcn2) null mice fail to adapt to prolonged
asparaginase treatment. A: percentage of
each experimental cohort (n  8–12 per
group at day 0) retained in the experiment
over the 14-day treatment schedule. None of
the GA mice completed the study due to
significant loss in body weight coupled with
behavioral morbidity. B: body weight change
of mice injected with saline or asparaginase
between days 0 and 14. C: average daily food
intake of mice fed ad libitum for up to 14 days
(black bars) or pair fed the same as amount as
the GA group for 8 days (white bars). D: body
weight change of pair-fed mice injected with
saline or asparaginase between days 0 and 8.
Values are means  SE. #Main effect of
asparaginase treatment to reduce body
weight. Labeled means without a common
letter differ (P  0.05, drug  strain inter-
action effect). WP, wild-type mice given
PBS; WA, wild-type mice injected with as-
paraginase; GP, Gcn2 null mice injected
with PBS; GA, Gcn2 null mice injected with
asparaginase.
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Lipid peroxidation. Malondialdehyde (MDA) is a product of lipid
peroxidation. The thiobarbituric acid-reactive substance (TBARS)
assay is a well-established assay for monitoring and screening lipid
peroxidation. MDA forms a 1:2 adduct with thiobarituric acid (TBA)
and can be measured colorimetrically using an MDA equivalent
standard. We detected the abundance of MDA in liver samples using
the OxiSelect TBARS assay kit (Cell Biolabs, San Diego, CA),
following the manufacturer’s instructions.
Body composition analysis. Body composition of the mice was
determined by magnetic resonance using an EchoMRI instrument
(Echo Medical Systems, Houston, TX). Conscious mice were briefly
(6 min) placed in a plastic restraining tube for the period of
measurement.
Serum measurements. The anti-FXa activity of anti-thrombin III
(ATIII) in plasma was determined by BIOPHEN Antithrombin 2.5 Kit
(ANIARA, West Chester, OH) following to the manufacturer’s in-
structions as previously reported (7a). Protein concentrations of
FGF21 were analyzed by solid phase sandwich enzyme-linked immu-
nosorbent assay using the Quantikine Mouse/Rat FGF-21 immunoas-
say (R&D Systems).
Immunoblot analysis. Weighed, frozen tissues were transferred to
microfuge tubes on ice, and protein lysates were prepared. The
homogenates were immediately isolated by centrifugation at 10,000 g
for 10 min at 4°C, and measurements of indicated protein levels and
phosphorylation states were carried out as previously described (12).
Phosphorylation of eIF2 was assessed using an antibody that recog-
nizes the alpha subunit only when it is phosphorylated at serine 51
(Cell Signaling Technology, Beverly, MA); results were normalized
for total eIF2	 levels with an antibody that recognizes the protein
irrespective of phosphorylation state (Santa Cruz Biotechnology,
Santa Cruz, CA). Phosphorylation of AMP-activated protein kinase-	
(AMPK	) was assessed using an antibody that recognizes the alpha
subunit only when it is phosphorylated at threonine 172 (Cell Signal-
ing Technology); results were normalized for total AMPK	 levels
with an antibody that recognizes the protein irrespective of phosphor-
ylation state (Cell Signaling Technology). Phosphorylation of acetyl-
CoA carboxylase (ACC) was assessed using an antibody that recog-
nizes phosphorylation at serine 79 (Cell Signaling Technology);
results were normalized for total ACC levels with an antibody that
recognizes the protein independent of phosphorylation state (Cell
Signaling Technology). ATIII was assessed using an antibody that
detects alpha and beta forms of ATIII (Epitomics, Burlingame, CA).
Microsomal triglyceride transfer protein (MTP) was purchased from
BD Biosciences (San Jose, CA). Apolipoprotein B-100 (ApoB-100)
was measured after electrophoresis of samples on 3 to 20% SDS-
acrylamide gradient gels. Samples were loaded onto the gradient gel
using a 3% SDS-acrylamide stacking gel. After blotting, ApoB was
measured using an antibody that detects both ApoB-48 and -100
(Abcam, Cambridge, MA). ApoB-48 was also detected and reacted
similarly to ApoB-100. Fatty acid synthase (FAS) was purchased from
Cell Signaling Technology, and CHOP/GADD153 antibody was pur-
chased from Santa Cruz Biotechnology (sc-7351). Antibodies to
ATF4 (1:500 dilution) and ATF5 (1:300 dilution) were prepared and
affinity purified as previously described (53). ATIII, MTP, ApoB-100,
and FAS were normalized by glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Blots were developed with enhanced chemiluminesence
(Amersham Biosciences). Protein expression was analyzed using a Car-
estream Gel Logic 6000 imager, and band density was quantitated using
carestream molecular imaging software (version 5.0).
Quantitative real-time PCR. Total RNA was extracted from frozen
tissue using TriReagent (Molecular Research Center, Cincinnati, OH)
followed by DNase treatment (VersaGene DNase Kit; Gentra Sys-
tems) (12). The A260/280 ratio was between 1.8 and 2.0 following
RNA purification using the RNeasy mini kit (Qiagen). Levels of
mRNAs were determined by quantitative PCR using TaqMan re-
agents. In this PCR assay, 1 g of the purified RNA solutions was
used for reverse transcription, which was carried out utilizing the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA). TaqMan Gene Expression Master Mix and
TaqMan Gene Expression Assays (Applied Biosystems) were then
used to conduct quantitative PCR.
Amplification and detection were performed using the StepOnePlus
Real-Time PCR System (Applied Biosystems) (12). Each mRNA
from a single biological sample was measured in triplicate and
normalized to 18S ribosomal RNA. Results were obtained by the
comparative Ct method and are expressed as fold change with respect
to the experimental control (WP).
Data analysis and statistics. Experimental results were analyzed
using SPSS Statistics software (IBM). Data were analyzed using
two-way ANOVA to assess main vs. interaction effects, with drug
treatment and mouse strain as independent variables. When interaction
effects were significant, differences between individual treatment groups
were assessed using the least significant difference post hoc test. Means
not sharing a common superscripted letter were considered statistically
different. The data presented are expressed as means  SE. The level of
significance was set at P  0.05 for all statistical tests.
Fig. 2. Asparaginase treatment promotes lipid accumulation in liver of Gcn2
null mice. A: paraffin-embedded liver sections (6 m) were stained with
hematoxylin and eosin and images taken using a 20 objective to visualize
general cellular structure. B: neutral lipid content of liver was examined by Oil
Red O stain and images captured using a 20 objective. C: liver mass,
expressed relative to body weight. D: liver triglyceride concentrations. Values
are means  SE; n  5–8 per group. All mice were pair fed the same amount
as the GA group. Labeled means without a common letter differ (P  0.05,
drug  strain interaction effect).
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GCN2 deletion renders mice unable to survive continued
asparaginase treatment. Asparagine is essential for the
growth of lymphoblastic tumors but dispensable for normal
tissues (30). Tumor cells that have lost the ability to make
asparagine cannot adapt to asparaginase and die (7). On the
other hand, somatic tissues possess the capacity to adapt to
asparaginase in part via AAR induction of cellular processes
(50). The role of GCN2 in the mechanism by which the liver
adapts to asparaginase was assessed by injecting asparagi-
nase into wild-type (WA) and Gcn2 null (GA) mice once
daily for up to 14 days and comparing outcomes to excipi-
ent-treated wild-type (WP) and Gcn2 null (GP) mice. To
avoid studying complications secondary to severe morbid-
ity, mice were euthanized when they lost 
20% body wt
and appeared unwell. Accordingly, all GA mice were eu-
thanized between 8 and 12 days of treatment due to their
deterioration in general appearance and behavior concomi-
tant with significant weight loss (Fig. 1, A and B). In
contrast, WA mice experienced little to no reduction in body
weight and appeared healthy throughout the entire 14-day
experiment. Asparaginase significantly reduced food intake
in GA mice (Fig. 1C); therefore, subsequent experiments
were performed by pair feeding all animals the same amount
as the GA mice, which consumed the least amount of food.
In these controlled feeding trials, asparaginase treatment
still reduced body weight below saline-injected mice (two-
way ANOVA P  0.05 main effect for treatment) with
losses in GA mice greatest (Fig. 1D). The pair-feeding trial
was conducted for only 8 days to avoid studying secondary
morbidities in GA mice.
Deletion of GCN2 promotes hepatic lipid accumulation
during prolonged asparaginase treatment. To compare the
histopathology resulting from asparaginase treatment in wild-
type vs. Gcn2 null mice, frozen liver samples were sectioned
and stained to visualize general cellular structure and neutral
lipid content. Liver sections taken from WA mice showed
minimal changes in histological appearance and low levels of
Oil Red O (Fig. 2, A and B). By comparison, GA liver sections
showed strong Oil Red O staining with well-defined enlarged
fat droplets in the cytosol relative to GP controls, reflecting
lipid accumulation. Furthermore, a small but significant in-
crease in liver weight relative to body weight was noted in GA
but not WA mice (Fig. 2C). Biochemical analysis confirmed an
approximately fourfold increase in triglyceride content in GA
livers relative to GP controls, whereas triglyceride content in
WA livers was similar to WP controls (Fig. 2D). In a previous
experiment, WA mice showed increased hepatic triglyceride
Fig. 3. Activation of the amino acid response (AAR) pathway in liver by asparaginase requires GCN2. A: asparaginase increases eukaryotic initiation factor 2
(eIF2) phosphorylation in wild-type but not Gcn2 null mice. Data are expressed as band density of serine 51 phosphorylated eIF2 relative to total expression levels
of eIF2 alpha subunit by immunoblot analysis. B: quantitative real-time PCR was employed to examine mRNA expression of Atf4, Atf5, Asns, 4ebp1, and Chop.
C and D: asparaginase increases protein expression of activating transcription factor 5 (ATF5) and CAAT enhancer binding protein homologous protein (CHOP)
in the liver of wild-type but not Gcn2 null mice by immunoblot analysis. All mice were pair fed the same amount as the GA group. Values are means  SE;
n  5–8 per group except in C and D, which was n  3–5 per group. Labeled means without a common letter differ (P  0.05, drug  strain interaction effect).
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after 6 days (50). Thus WA liver had adapted to the amino acid
stress, whereas livers from Gcn2 null mice continued to decline
metabolically.
GCN2 is the primary regulator of the AAR in liver during
prolonged asparaginase treatment. Consistent with our previ-
ous work reporting induction of the AAR in liver by aspara-
ginase following both 1 and 6 days of treatment (12, 50), eIF2
phosphorylation was greatly elevated in WA livers compared
with WP controls (Fig. 3A). Treatment of control mice with
asparaginase increased hepatic mRNA levels of the transcrip-
tion factors Atf4 and Atf5, as well as their target genes,
eukaryotic translation initiation factor 4E-binding protein 1
(4ebp1), asparagine synthetase (Asns), and CAAT enhancer
binding protein homologous protein (Chop) (Fig. 3B). In stark
contrast, induction of the hepatic AAR as a result of asparagi-
nase treatment was completely blocked in Gcn2 null mice, a
result again consistent with previous reports (12, 50). Exami-
nation of protein expression revealed very low or no ATF4
protein expression across treatment groups (data not shown).
ATF5 protein increased slightly (P  0.08) in wild-type mice
treated with asparaginase (Fig. 3C), whereas CHOP protein
expression significantly increased in the livers of WA but not
GA mice (Fig. 3D).
GCN2 regulates liver FGF21 expression and lipid metabo-
lism during asparaginase treatment. We next addressed pos-
sible mechanisms for the accumulation of lipids in the liver of
GA mice. One powerful regulator of hepatic metabolism is
FGF21, a peptide hormone expressed in numerous tissues
including the liver. Circulating concentrations of FGF21 are
reportedly derived from the liver (35). FGF21 causes pleiotro-
pic effects on metabolism, including regulation of fat oxida-
tion, ketogenesis, and gluconeogenesis in the liver (51). Recent
reports collectively show hepatic expression and circulating
levels of Fgf21 increased by amino acid-deficient diets in a
manner requiring GCN2 (18, 34). Similar to protein deficiency,
we found an 17-fold increase in Fgf21 mRNA levels in liver
and an 20-fold increase in serum FGF21 protein concentra-
tion in WA mice, relative to WP controls (Fig. 4, A and B).
Conversely, GP and GA mice possessed low levels of hepatic
Fgf21 mRNA and serum Fgf21 levels. An13-fold increase in
Fgf21 mRNA expression occurred after a single injection of
asparaginase, which was also GCN2 dependent (WP: 0.74 
0.35; WA: 9.53  4.58; GP: 1.19  0.28; and GA: 0.92 
0.46). Thus hepatic expression and circulating concentrations
of FGF21 by asparaginase required GCN2.
FGF21 is reported to regulate energy metabolism and mito-
chondrial oxidative function through activation of AMPK and
sirtuin (SIRT1) (15). In the current study, large increases in
circulating FGF21 in wild-type mice treated with asparaginase
were not accompanied by increases in phosphorylation of
AMPK or expression of downstream target genes such as
peroxisome proliferator-activated receptor-gamma coactiva-
tor-1	 (PGC-1	) (Table 1). Rather, in GA mice, as FGF21
levels were depressed, so was the expression of many hepatic
genes involved in mitochondrial function, at least directionally
if not significantly. For example, phosphorylation of ACC, a
marker of AMPK activity, decreased 25% in GA relative to GP
controls (P  0.07), and expression levels of Pgc1 and Tfam
mRNAs were reduced 45% (P  0.09) and 54% (P  0.06),
respectively. Similar directional trends were also noted in Sirt
and Nrf1 mRNA, in total suggesting compromised mitochon-
drial function in the liver of GA mice.
Genes related to lipid metabolism were largely unchanged in
WA mice compared with WP controls. However, GA mice
showed a sharp decline in the levels of gene transcripts related
to lipid synthesis, including the transcription factor Ppar and
its target Atp-citrate-lyase and Scd1, as well as Fas mRNA
(Fig. 5A) and FAS protein expression (Fig. 5B). In GA mice
there was also decreased expression of genes involved in lipid
oxidation, including Ppar and its target genes Acox (peroxi-
somal lipid oxidation) and Acadm (beta-oxidation) and genes
facilitating intracellular lipolysis (Atgl) and intravascular lipol-
ysis (Lpl) (Fig. 5A). These results suggest that loss of GCN2
disrupts the expression of hepatic genes involved in lipid
synthesis and turnover. No changes in gene expression across
treatment groups were found in Cd36, a fatty acid transporter;
Srebp1/2, which regulates lipid and cholesterol metabolism;
G6pc, encoding the final step in gluconeogenesis; and two lipid
droplet protein genes, Fsp27 and Cidea (Table 1).
Deletion of GCN2 impairs triglyceride secretion during
prolonged asparaginase treatment via reduced ApoB-100
expression. Both the capacity for lipid synthesis and break-
down appeared reduced; thus neither process could explain the
observed hepatic lipid accumulation. Therefore, we next mea-
sured triglyceride secretion by the liver. VLDL-TG secretion
rates were calculated from the slope of the linear regression
describing the rise in blood triglyceride concentration over
time after intraperitoneal injection of tyloxapol, an inhibitor of
triglyceride clearance (28). Employing this method, we ob-
served a significant reduction in the rate of triglyceride secre-
Fig. 4. Induction of fibroblast growth factor 21 (FGF21) by asparaginase
requires GCN2. A: hepatic Fgf21 mRNA expression was determined by
quantitative real-time PCR. B: FGF21 protein concentration in serum analyzed
by enzyme-linked immunoassay. All mice were pair fed the same amount as
the GA group. Values are means  SE; n  5–8 per group. Labeled means
without a common letter differ (P  0.05, drug  strain interaction effect).
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tion from the liver in GA mice relative to GP controls. In
contrast, triglyceride secretion by WA liver tended to increase
relative to WP controls (Fig. 5C).
An inability to assemble VLDL-TG could explain the ob-
served impaired triglyceride secretion in GA mice. Therefore,
we measured protein expression of MTP and ApoB-100, which
are both crucial to the assembly and secretion of triglyceride
from liver (40). Contrary to the predicted hypothesis, aspara-
ginase increased MTP protein concentrations in the livers of
both WA and GA mice (two-way ANOVA significant main
effect, P  0.05; Fig. 5D). However, asparaginase reduced
hepatic ApoB-100 (and ApoB-48, data not shown) protein
levels in GA livers (Fig. 5E), consistent with the decreased
triglyceride secretion rate in GA mice.
Lipid peroxidation of accumulated lipids leads to liver
dysfunction, coagulopathy. Oxidative stress enhances ApoB-
100 degradation (38), and the AAR is important for promoting
oxidative stress defenses (27); therefore, we measured the
oxidative status in livers following asparaginase treatment.
Consistent with this hypothesis, there was a significant increase
in MDA concentrations (an indicator of lipid peroxidation) in
GA livers (Fig. 6A), along with a decrease in the mRNA
expression of the critical endogenous antioxidant GPX1 (Fig.
6B). No significant changes were found in protein carbonyla-
tion in liver (Table 1).
Previous studies described asparaginase treatment as causing
a “temporary conformational disease,” promoting the retention
and/or aggregation of labile secretory proteins made by the
liver such as ATIII, a factor regulating hemostasis (29). ATIII
activity is reportedly reduced by lipid peroxides and is used as
a marker of liver dysfunction and disease (36). To further
explore the mechanism by which asparaginase causes reduced
ATIII, liver mRNA and protein expression of ATIII, as well as
its anti-FXa activity in serum, were measured. In GA mice,
significant declines in hepatic mRNA (Fig. 6C) and protein
(Fig. 6D) levels of ATIII were noted, as well as significantly
reduced ATIII anti-FXa activity in plasma (Fig. 6E) relative to
GP controls. While not measured directly, we speculate that
other factors involved in regulating blood clotting were also
reduced in GA mice, as GA mice treated with asparaginase for
longer than 8 days showed evidence of internal bleeding within
the peritoneal space, indicating coagulopathy.
Deletion of GCN2 impairs AAR signaling and FGF21
expression in white adipose tissue during prolonged
asparaginase. Asparaginase did not alter relative or total body
fat mass, inguinal fat pad weights, or fat-free mass in wild-type
mice (Fig. 7, A–D). By comparison, GA mice had reduced total
body fat mass (Fig. 7A) and reduced inguinal fat mass (Fig. 7,
C and D). To uncover the molecular basis for these differences
in body composition, expression levels of AAR targets were
investigated in inguinal fat pads. Unlike liver, asparaginase did
not activate the AAR in the adipose of wild-type mice (Fig.
7E). Yet, similar to liver, administration of asparaginase to GA
mice decreased mRNA expression of Atf5 by approximately
threefold in inguinal fat pads relative to GP controls. Also,
consistent with decreases in fat mass in GA mice, significant
decreases in the expression levels of Fgf21, Ppar, Fas,
Atp-citrate-lyase, and Scd1 (Fig. 7E) were observed, as well as
decreased FAS protein expression (Fig. 7F) and a trend for
decreased CD36 levels (P  0.09; Table 1), suggesting de-
creased lipid transport in GA mice. Finally, a trend for reduced
expression of FGF21-regulated genes in the adipose tissue of
GA mice was evident, specifically a 43% decline in Pgc1
Table 1. Liver and adipose responses following 8 days asparaginase treatment in wild-type mice and mice deleted for GCN2
WP WA GP GA Strain Treatment S  T
Liver
p-AMPK	-Thr172/T-AMPK	 8.54  1.59 9.35  1.60 8.33 1.28 8.98  1.05 No No No
p-ACC-Ser79/T-ACC 9.73 1.58 10.63 1.80 8.74  1.01 6.53  0.70 No No 0.07
Pgc1 mRNA 0.83 0.18 0.85  0.12 1.04 0.21 0.57  0.09 No No 0.09
Sirt1 mRNA 0.94 0.17 1.18  0.24 1.11 0.21 0.83  0.12 No No No
Tfam mRNA 1.00 0.18 1.15  0.18 1.16 0.22 0.53  0.09 No No 0.06
Nrf1 mRNA 0.91 0.16 1.18  0.24 1.26 0.27 0.82  0.13 No No No
Cd36 mRNA 0.98 0.19 0.98  0.18 1.05 0.15 0.92  0.07 No No No
Srebp1 mRNA 1.13 0.16 0.98  0.23 1.13 0.18 0.84  0.05 No No No
Srebp2 mRNA 1.31 0.22 1.14  0.09 1.08 0.14 0.81  0.27 No No No
G6pc 1.12  0.22 1.41  0.39 1.12 0.11 1.09  0.18 No No No
Fsp27 mRNA 1.05 0.17 1.25  0.22 1.15 0.25 0.85  0.39 No No No
Cidea mRNA 3.65 1.86 5.27  2.65 7.45 1.80 3.02  2.12 No No No
Protein carbonylation 74.27 8.02 72.32  7.17 78.60 5.08 74.70 8.98 No No No
White adipose
Asns mRNA 1.01  0.12 0.86  0.06 0.83 0.11 0.33  0.05 No No 0.05
Pgc1 mRNA 1.12 0.25 1.21  0.17 1.23 0.22 0.70  0.17 No No 0.1
Sirt1 mRNA 1.06 0.17 1.35  0.14 2.04 0.53 0.89  0.18 No No No
Tfam mRNA 1.37 0.47 0.92  0.08 1.18 0.25 0.41  0.05 No No 0.1
Nrf1 mRNA 1.03 0.14 1.30  0.16 2.03 0.44 0.95  0.19 No No No
Cd36 mRNA 1.02 0.10 1.73  0.32 1.43 0.33 0.83  0.15 No No 0.09
Values are means  SE; n  5–8 per group. WP, wild-type mice injected with PBS; WA, wild-type mice injected with asparaginase; GP, general control
nonderepressible 2 null (Gcn2 null) mice injected with PBS; GA, Gcn2 null mice injected with asparaginase. Mice were pair fed the same amount as the GA
group. Quantitative real-time PCR was employed to measure relative mRNA levels after 8 days of injections with ASNase or PBS. Target gene transcripts were
normalized by 18S rRNA control. Phosphorylation state and protein expression were assessed by immunoblot analyses. Antibodies specific for phosphorylated
AMP kinase alpha (p-AMPK	) and acetyl-CoA carboxylase (p-ACC) were quantified relative to total p-AMPK	 and total ACC, respectively. Protein
carbonylation was measured in mouse livers using the Biovision Protein Carbonyl Content Assay Kit, following the manufacturer’s instructions. Protein
carbonylation was expressed as nmol carbonyl/mg protein. In all measurements shown, main effects of GCN2 deletion (strain) and asparaginase (treatment) vs.
their interaction (S  T) were detected by two-way ANOVA. Statistical trends are noted by the P value; No  not significant, P 
 0.1.
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(P  0.15), a 57% decrease in Sirt1 (P  0.12), and a 53%
decrease in Nrf1 mRNA (P  0.10) (Table 1).
DISCUSSION
In the liver, asparaginase inhibits protein synthesis and
promotes steatosis and hepatic dysfunction (42, 43, 45). He-
patic steatosis and dysfunction leading to liver failure and
secondarily to coagulopathy and thromboembolism are among
the most serious side effects associated with asparaginase
treatment (10, 23). The data presented in this effort describe
how the GCN2-directed AAR controls the ability of the liver to
adapt to asparaginase. Loss of GCN2 corresponds with reduced
hepatic triglyceride secretion and lipid turnover and resultant
hepatic lipid accumulation. Peroxidation of these accumulated
lipids alongside other oxidative and inflammatory stress signals
(50) collectively promotes hepatic dysfunction, culminating in
coagulopathy and morbidity.
Fatty liver could be the result of deranged lipid turnover in
liver, impaired triglyceride secretion by the liver, or impaired
interorgan fat metabolism. The current work shows all three
pathways were affected by asparaginase treatment and influ-
enced by loss of Gcn2. Concerning hepatic lipid turnover, there
was a substantial decline in the expression of genes related to
lipid synthesis (Fas, Atp-citrate lyase), oxidation (Acox,
Acadm), and lipolysis (Lpl, Atgl) in Gcn2 null mice treated
with asparaginase. One interpretation of these data is that one
or more factors regulated by GCN2 play a permissive role in
maintaining lipid metabolism during amino acid stress. These
factors maintain expression of relevant genes by counteracting
other inhibitory signals or molecular repressors during aspar-
aginase to allow for metabolic adaptation.
An outcome identified in Gcn2 null mice treated with as-
paraginase was impaired hepatic VLDL-TG secretion in con-
cert with decreased ApoB-100 protein concentrations. We
hypothesize the decline in ApoB-100 is a result of increased
oxidative stress, a known stimulus for ApoB-100 degradation
(22, 38). Previous studies point to the GCN2-eIF2 AAR path-
way as critical for regulating oxidative defense systems (5, 14),
and Gcn2 null mice fed a leucine-devoid diet demonstrate
increased oxidative damage in the liver (3, 16). It may be that
sustained loss of the AAR negatively affects production of
antioxidants such as GPX1, compromising redox balance. An
alternative or additional influence could relate to sortilin 1, a
multiligand transmembrane sorting receptor located in the
trans-Golgi network and early endosomes (1, 9). Overexpres-
sion of sortilin 1 in mice promotes ApoB degradation and
Fig. 5. Hepatic triglyceride metabolism and lipid secretion are impaired in Gcn2 null mice administered asparaginase. A: quantitative real-time PCR was
employed to examine mRNA expression of Ppar, Ppar, Fas, Atp citrate lyase, Scd1, Acox, Acadm, Atgl, and Lpl. B: expression of fatty acid synthase (FAS)
protein relative to GAPDH was analyzed by immunoblot. C: mice were injected with tyloxapol to inhibit breakdown of triglycerides (TG) in plasma. The rate
of appearance of blood TG during this blockade was measured to determine TG secretion from liver. D: protein expression of microsomal triglyceride transfer
protein (MTP) relative to GAPDH was analyzed by immunoblot. E: protein expression of apolipoprotein B-100 (ApoB-100) relative to GAPDH was analyzed
by immunoblot. Values are means  SE; n  5–8 per group. #Main effect of treatment. Labeled means without a common letter differ (P  0.05, drug  strain
interaction effect).
E289ASPARAGINASE INCREASES FGF21
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00361.2014 • www.ajpendo.org







reduced VLDL secretion (46). On the other hand, sortilin 1 is
decreased in obesity and diabetic models and appears to be
repressed by mammalian target of rapamycin (mTOR), extra-
cellular signal-regulated kinase (ERK), and endoplasmic retic-
ulum stress (1, 9). Future studies examining sortilin-1 expres-
sion and localization, its binding activity to lipoproteins, and
the factors that control its expression during asparaginase in the
presence vs. absence of GCN2 are necessary to adequately
clarify the relationship between the AAR and sortilin 1 func-
tion.
A recent report by Xu et al. (52) describes how Gcn2 null
mice exhibit elevated serum triglycerides but reduced hepatic
triglyceride storage alongside lower expression levels of the
lipid droplet proteins Fsp27 and Cidea. These outcomes were
detectible in mice provided a medium-fat (22 kcal%) chow diet
but not mice maintained on a low-fat (13 kcal%) chow diet. In
the current study, mice were maintained on a low-fat chow diet
and so it was not unexpected to find gene expression of Fsp27
and Cidea similar among treatment groups (Table 1). However,
we note that the report by Xu et al. (52) also shows Gcn2 null
mice to possess increased serum triglyceride levels despite
reduced hepatic triglyceride concentrations. Our liver triglyc-
eride data in Fig. 2, B and D, agree with this report, and our
triglyceride secretion data extend these findings by suggesting
that the livers of Gcn2 null mice have enhanced triglyceride
secretion, providing additional explanation as to why Gcn2
null mice have reduced liver triglycerides yet elevated circu-
lating triglycerides.
A third mechanism for metabolic dysfunction relates to
impaired interorgan fat metabolism. In other experimental
models of fasting and protein restriction, increased circulating
FGF21 facilitates mitochondrial oxidative function in adipose,
resulting in increased energy expenditure (15, 18, 34). These
responses were not identified in mice treated with asparagi-
nase. Instead, mice deleted for Gcn2 demonstrated reduced
circulating FGF21 when challenged with asparaginase, which
corresponded with dampened mitochondrial function in liver
and adipose. We propose that FGF21 is one of the factors that
serves to maintain homeostasis and allow for metabolic adap-
tation during asparaginase treatment. The endocrine actions of
FGF21 in this experimental model and differential outcomes in
peripheral tissues have yet to be fully explored. Additional
exploration of the AAR in the presence vs. absence of GCN2
and/or FGF21 (whole body compared with tissue specific) is
warranted to fully understand the metabolic roles of FGF21 in
response to asparaginase.
We were also interested in the role of GCN2 in regulation of
hemostasis during asparaginase treatment. Upon dissection of
mice, we observed that organs of the wild-type mice appeared
normal. However, in GA mice, there was pronounced internal
bleeding, and some livers appeared necrotic. Consistent with
this observation, we found a significant decline in the mRNA
and protein levels of ATIII in liver, as well as low ATIII
anti-FXa activity in serum. Acquired type I ATIII deficiency is
often a side effect of liver failure (36). These data demonstrate
that GCN2 has a critical role for regulating the health of the
liver and liver dysfunction in GA mice promotes ATIII defi-
ciency, leading to deranged hemostasis.
To what extent ATF4 modulates the transcriptome and
directs homeostatic outcomes during asparaginase is unclear.
Translational induction of ATF4 by cellular stress is described
in detail (31, 48) and, in the case of endoplasmic reticulum
stress, demonstrated in both cell lines and tissues from exper-
imental animal models (32, 47). However, this same level of
corroboration across model systems cannot be claimed for
amino acid deprivation. While in vitro studies report increased
Fig. 6. Loss of AAR promotes oxidative stress and evidence of developing coagulopathy in liver during asparaginase. A: thiobarbituric acid reactive substances
assay (TBARS) was performed to test for lipid perodixation in mice livers. Thiobarbituric acid reacts with malondialdehyde (MDA), a by-product of lipid
peroxidation, to yield a wavelength at 532 nm that was detected by spectrophotometry analysis. B: quantitative real-time PCR was employed to examine relative
mRNA expression of Gpx1. C: quantitative real-time PCR was employed to measure mRNA expression of anti-thrombin III (AtIII). D: levels of ATIII protein
at the alpha and beta subunits were measured by immunoblot analysis. Results shown beneath the representative immunoblot are expressed as the density of ATIII
relative to GAPDH. E: results show the anti-FXa activity of ATIII in plasma as percentage of WP. All mice were pair fed the same amount as the GA group.
Values are means  SE; n  5–8 per group. Labeled means without a common letter differ (P  0.05, drug  strain interaction effect).
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ATF4 protein during amino acid withdrawal (4, 26), studies in
animals are inconsistent (17, 18, 34, 50). This disparity can be
due to a number of reasons aside from previous concerns
related to antibody specificity and sensitivity. First, induction
of the AAR is dynamic and is tailored to the amplitude and
extent of the stress. As such, attempts to visualize both protein
and gene expression may not always be successful in a single
point in time. We suggest that incongruence between ATF4
protein and gene expression in our model may be related to the
time-bound nature of this study. Future time course studies
may be necessary to resolve this possibility. Second, it is
feasible to consider that in mouse liver other transcription
factors such as ATF5 and CHOP may be important contribu-
tors to the regulation of the AAR at the level of translational
control. Both ATF4 and CHOP are reportedly essential for
FGF21 expression during endoplasmic reticulum stress (49),
and ATF5 can be regulated in the liver similar to ATF4 (53).
At least one report suggests that ATF5 may contribute signif-
icantly to the regulation of Asns during amino acid stress in
mouse liver (17). Ribosomal profiling and other methods to
explore the translational control of gene expression may be
necessary to fully understand the contribution of ATF4 to the
overall AAR to asparaginase.
In summary, GCN2 is essential for adaptations from aspar-
aginase treatment. Mice deficient in GCN2 are unable to
induce the AAR and suffer a greater degree of hepatotoxicity
from asparaginase. The present findings are in agreement with
two reports correlating polymorphisms in ASNS and ATF5
with adverse outcomes to asparaginase treatment humans un-
dergoing treatment for acute lymphoblastic leukemia (8, 44).
The combination of this type of preclinical exploration along-
side investigation of leukemic patient profiles may guide the
development of tests that successfully predict who is at risk for
developing complications arising from asparaginase treatment
and facilitate the development of a more individualized and
thus effective treatment regimen.
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